The recent release by WHO of new recommendations aimed at speeding up tuberculosis drug susceptibility testing using a rapid molecular MTBDRsl test and use of shorter multidrug-resistant tuberculosis (MDR-TB) treatment regimens is a long-awaited development. Although the new recommendations are welcomed, there are concerns about whether the shorter MDR-TB treatment regimen is likely to be effective in all geographical settings.
Download the full article here.
Source: The Lancet